Several imaging features were more common in MS than in AQP4 or MOG antibody disease.
Patients are sometimes misdiagnosed with multiple sclerosis (MS) when they actually have neuromyelitis optica spectrum disorder (NMOSD), with aquaporin-4–positive disease (AQP4+) or myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).
To differentiate MS from AQP4+ and MOGAD, investigators conducted a cross-sectional study that compared brain, spinal cord, and optic nerve MRI features among 91 patients in the UK: 31 with MS, 30 with AQP4+, and 30 with MOGAD.
Key results were as follows:
White matter lesions were detected in more MS patients than NMOSD or MOGAD patients (100% vs. 83% or 27%, respectively).
The central vein sign (CVS) within white matter lesions was detected in more MS patients than AQP4+ or MOGAD patients (10…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)